Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Middlemen’ Markups Are Penalizing Patients, Says AAM

Cash Prices For Generic Drugs Are Substantially Higher Than Manufacturer Prices

Executive Summary

The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.

You may also be interested in...



US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings

The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines. 

US Patients Increasingly Reliant On Pharmacy Discount Cards For Generics

IQVIA has published a white paper examining the growing reliance on pharmacy discount cards to pay for prescriptions in the US.

Increased Transparency Key To Combating Drug Shortages, Says US Industry Alliance

The closure of a Teva manufacturing plant in California has raised concerns around access a number of medicines, something the End Drug Shortages Alliance says could be avoided through increased market transparency.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel